Bone disease in patients with chronic kidney disease under conservative management
Keywords:
Renal osteodystrophy, Kidney diseases, Chronic kidney failure, Renal dialysis, Bone resorptionAbstract
CONTEXT AND OBJECTIVE: Few studies have focused on bone disease in patients with chronic kidney disease under conservative treatment. The objective was to evaluate bone disease in patients with chronic kidney disease. DESIGN AND SETTING: Case series, at the Nephrology Division, Hospital Universitário Pedro Ernesto. METHODS: 131 patients with creatinine clear- ance from 10 to 60 ml/min/1.73 m² were fol- lowed up for at least one year. Serum creatinine, albumin, calcium, phosphorus, alkaline phos- phatase, total CO2 (tCO2), intact parathyroid hormone (iPTH), and alkaline phosphatase were measured. Creatinine clearance was calculated from 24-hour urine creatinine measurements and protein ingestion estimates from urea assays. RESULTS: Patients presenting creatinine clearance < 30 ml/min/1.73 m² had higher iPTH values, but normal serum levels for calcium, phosphorus, alkaline phosphatase and tCO2. Patients present- ing iPTH values of twice the normal upper limit (144 pg/ml) showed lower tCO2 values. Bone al- kaline phosphatase was evaluated in 37 patients with creatinine clearance < 30 ml/min/1.73 m², showing correlation with alkaline phosphatase but not with parathyroid hormone. Bone biopsy on nine patients with creatinine clearance < 30 ml/min/1.73 m² and iPTH > 144 pg/ml showed osteitis fibrosa (4), mild lesion (4) and high turnover (1). CONCLUSION: The present data suggest the importance of early control for iPTH and metabolic acidosis, among patients under conservative management for chronic kidney disease, in order to prevent complications related to bone disease.
Downloads
References
Hutchison AJ, Whitehouse RW, Boulton HF, et al. Correla- tion of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44(5):1071-7.
Carvalho AB, Lobao RR, Cuppari L, Draibe SA, Ajzen H. Does hypophosphataemia induce hypoparathyroidism in pre-dialysis patients?. Nephrol Dial Transplant. 1998;(13 Suppl 3):12-4.
Torres A, Lorenzo V, Hernández D, et al. Bone disease in pre- dialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int. 1995;47(5):1434-42.
Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross sectional study. Nephrol Dial Transplant. 1996;11(5):813-9.
Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358-63.
Baker LR, Abrams L, Roe CJ, et al. 1,25(OH)2D3 administra- tion in moderate renal failure: a prospective double-blind trial. Kidney Int. 1989;35(2):661-9.
Ho LT, Sprague SM. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Semin Nephrol. 2002;22(3):268-75.
Eriksen EF, Brixen K, Charles P. New markers of bone metabo- lism: clinical use in metabolic bone disease. Eur J Endocrinol.
;132(3):251-63.
Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56(3):1084-93.
Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7(3):506-12.
Duarte ME, Peixoto AL, Pacheco AS, et al. The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings. Rev Paul Med.1998;116(5):1790-7.
Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000;11(2):330-4.
Martínez R, Saracho R, Moina I, Montenegro J, Llach F. Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure? Nephrol Dial Transplant. 1998;13(Suppl 3):9-11.
Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemilumi- nometric assay. J Clin Endocrinol Metab. 1987;65(3):407-14.
Malluche HH, Monier-Faugere MC. Understanding and manag- ing hyperphosphatemia in patients with chronic renal disease.
Clin Nephrol. 1999;52(5):267-77.
Bushinsky DA. Hydrogen Ions. In: Bushinsky DA, editor. Renal Osteodystrophy. New York: Lippincott-Raven; 1998. p.103-27.
Solal ME, Sebert JL, Boudailliez B, et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991;73(3):516-24.
Jarava C, Armas JR, Salgueira M, Palma A. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant. 1996;11(Suppl 3):43-6.
Bervoets AR, Spasovski GB, Behets GJ, et al. Useful bio- chemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41(5):997-1007.
Lafage-Proust MH, Combe C, Barthe N, Aparicio M. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab. 1999;84(2):512-9.
